Business Broker vs Investment Bank for Home Care Agency Sales

Choosing the advisor who will sell your home care agency is one of the highest-leverage decisions in the entire process. The right advisor materially affects valuation, deal structure, certainty of close, and post-close terms. The wrong advisor — or no advisor at all — leaves significant value on the table and can put the transaction at risk.

This guide explains the differences between the three main advisor categories, how to choose between them, and what to look for in each.

---

The Three Advisor Categories

1. Business Brokers

Business brokers serve smaller, owner-operated businesses across many industries — restaurants, retail, manufacturing, services, and including home care at the lower end. Characteristics:

• Listing-based marketing model (often public or semi-public listings)
• Cross-industry generalism, with healthcare as one of many sectors
• Transactional approach — find a buyer, complete the deal
• Limited buyer relationships in any specific industry
• Fee structures often heavier on retainer and/or higher commission percentages on smaller deals
• Generally serve businesses with under approximately $1M to $2M of enterprise value

Strengths: access for smaller agencies that wouldn’t attract specialist attention; broad buyer outreach (including individual buyers).

Weaknesses: limited buyer relationships in healthcare, weaker process structure, less expertise on healthcare-specific diligence and structure issues.

2. Healthcare M&A Advisors and Boutique Investment Banks

Healthcare-specialized M&A advisors and boutique investment banks focus on the home-based care, behavioral health, and adjacent healthcare services markets. Characteristics:

• Industry specialization with deep buyer relationships
• Structured competitive process model (CIM, targeted buyer outreach, IOIs, management presentations, LOIs, diligence, close)
• Sophisticated understanding of healthcare regulatory and operational diligence
• Success-fee dominant fee structures
• Generally serve businesses with $500K of EBITDA and above

Strengths: buyer relationships, healthcare expertise, process discipline, valuation outcomes.

Weaknesses: typically don’t take engagements below a certain threshold (commonly $300K–$500K EBITDA); higher absolute fees (though usually justified by valuation lift).

3. Larger Middle-Market and Bulge-Bracket Investment Banks

Larger investment banks (middle-market dedicated firms; the larger national and global investment banks for the top of the market) serve the largest transactions. Characteristics:

• Sophisticated process management
• Deep relationships with the largest PE sponsors and strategic acquirers
• Premium fee structures
• Generally serve businesses with $5M to $10M of EBITDA and above (varies by firm)

Strengths: access to the deepest buyer pool for large transactions; deal-making sophistication for complex structures.

Weaknesses: not interested in or appropriate for smaller agencies; can be overkill for transactions that don’t require their bandwidth.

---

How to Choose

Size Drives the Decision

The single biggest factor is your agency’s EBITDA scale and the resulting transaction size:

Agency EBITDA	Typical Right Advisor
Under $300K	Generalist business broker (or no advisor for very small)
$300K–$500K	Healthcare-specialized broker or smaller M&A advisor
$500K–$2M	Healthcare-specialized M&A advisor or boutique investment bank
$2M–$10M	Boutique or middle-market healthcare investment bank
$10M+	Middle-market or larger investment bank

These ranges are approximate. Specific agency profile (segment, complexity, buyer pool) shifts the right answer up or down.

Complexity Matters

Agencies with regulatory complexity — Medicare-certified home health, hospice, multi-state operations, recent compliance issues, complex payer mix — benefit disproportionately from healthcare specialization, even at smaller scales. Generalist business brokers struggle with the diligence and structure issues these create.

Buyer Pool Composition Matters

If your most likely buyer pool is dominated by PE-backed platforms (which is the case for most home-based care above $500K EBITDA), specialized advisors with established relationships to those platforms produce materially better outcomes. Generalist brokers don’t have those relationships.

Process Sophistication Matters

A structured competitive process — CIM, targeted buyer outreach to 15–40 curated buyers, staged diligence, multiple competing offers, structured negotiation — typically generates 15–30 percent higher outcomes than a listing-based or single-buyer approach. The capability to run that process is the difference between most business brokers and most healthcare M&A advisors.

---

What a Good Healthcare M&A Advisor Actually Does

For agencies that fit the healthcare M&A advisor / investment bank profile, here is what the engagement actually delivers:

Pre-Process

• Sell-side analysis and valuation modeling
• Strategic positioning and growth narrative development
• Add-back analysis and EBITDA normalization (often coordinated with QoE)
• CIM and management presentation development
• Buyer list curation and process design

Marketing

• Confidential, targeted buyer outreach
• NDA management
• Initial buyer education and qualification
• Coordinated CIM distribution

Process Management

• IOI solicitation and evaluation
• Buyer selection for second round
• Management presentation coordination
• Site visit and Q&A management
• LOI solicitation and evaluation
• Negotiation of letter of intent terms (price, structure, exclusivity, conditions)

Diligence and Close

• Data room management
• Diligence coordination across financial, legal, regulatory, operational, HR
• Issue navigation as items arise in diligence
• Definitive agreement negotiation in coordination with counsel
• Closing coordination

Beyond Process

• Transition planning support
• Post-close earnout monitoring (where applicable)
• Founder transition coordination

The best advisors are deal-experienced operators who can navigate the inevitable issues that arise in any transaction without the deal blowing up.

---

Red Flags in Choosing an Advisor

Watch for:

• Large upfront fees with little success fee — alignment is poor; advisor gets paid whether or not the deal closes well.
• Public listings of healthcare businesses — confidentiality matters in home-based care; public listings can damage relationships with employees, referral sources, and payers.
• No specific buyer relationships demonstrated — “we have a database of buyers” is not the same as “we have closed three transactions with [specific platform] in the last 18 months.”
• Inability to discuss recent transactions — advisors who can’t talk about recent comparable transactions (under appropriate confidentiality) don’t have the volume of recent deals you want.
• Overly optimistic valuation pitches — advisors who pitch unrealistic valuations to win the engagement, then fail to deliver, are common. Compare valuation discussions across multiple advisors.
• Generalist business sale templates — CIM, process structure, and buyer outreach should be tailored to home-based care, not adapted from a generic business sale template.
• Lack of healthcare regulatory understanding — if the advisor can’t speak fluently about CHOW, EVV, OIG screening, Medicare cap, payer contract assignment, you have the wrong advisor.

---

Fee Structures

Most healthcare M&A advisors and investment banks use some combination of:

• Engagement fee or work fee — modest upfront fee, often $25K to $100K depending on engagement size
• Monthly retainer — sometimes used during process
• Success fee — percentage of transaction value, typically 1 to 5 percent depending on transaction size, often with minimums and tiered structures
• Lehman or Double Lehman scales — common fee structures that scale percentage with transaction value

For the right advisor, the fee is meaningfully smaller than the valuation lift they deliver. The wrong advisor charges the same fee and produces a weaker outcome.

---

What About Selling Without an Advisor?

For very small agencies (under $200K of EBITDA), selling directly to a known buyer can make sense. For agencies above that threshold, going to market without advisory support typically:

• Achieves materially lower valuation (often 20–40 percent lower)
• Results in less favorable deal structure
• Creates higher execution risk
• Generates more diligence-driven discounts
• Produces worse post-close outcomes

The owner is also typically running the agency through the process, which divides attention and harms operational results during the diligence period — which itself becomes a discount.

The cases where unrepresented sale makes sense are narrow.

---

Strategic Implications

For most home care, home health, hospice, pediatric, and behavioral health agencies above $500K of EBITDA, the right advisor is a healthcare-specialized M&A advisor or boutique investment bank with active buyer relationships, deep healthcare expertise, and a structured competitive process. The right choice typically pays for itself many times over in valuation lift and deal quality.

If you would like to understand what the right advisor profile looks like for your specific agency, contact us for a confidential conversation.